モノクローナル抗体 (Japanese Wikipedia)

“Dr. George Pieczenik”. LMB Alumni. MRC Laboratory of Molecular Biology (LMB) (17 September 2009). 23 December 2012時点のオリジナルよりアーカイブ。17 November 2012閲覧。

australianprescriber.com

Australian Prescriber (2006). “Monoclonal antibody therapy for non-malignant disease”. Australian Prescriber 29 (5): 130–133. doi:10.18773/austprescr.2006.079.

bloomberg.com

“Bristol-Myers Squibb Bets Big on a Mouse”. Bloomberg.com. Bloomberg L.P.. 2021年5月28日閲覧。

cam.ac.uk

www2.mrc-lmb.cam.ac.uk

“Dr. George Pieczenik”. LMB Alumni. MRC Laboratory of Molecular Biology (LMB) (17 September 2009). 23 December 2012時点のオリジナルよりアーカイブ。17 November 2012閲覧。

cancer.gov

home.ccr.cancer.gov

“Cytochrome P450 Mediated Drug and Carcinogen Metabolism using Monoclonal Antibodies”. home.ccr.cancer.gov. 2019年6月20日時点のオリジナルよりアーカイブ。2021年5月29日閲覧。

cancer.org

“Monoclonal antibodies to treat cancer | American Cancer Society”. www.cancer.org. 2018年4月19日閲覧。

cancernetwork.com

Takimoto CH, Calvo E. (January 01, 2005) "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management

cell.com

Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ (November 1999). “Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery”. Trends in Pharmacological Sciences 20 (11): 432–8. doi:10.1016/S0165-6147(99)01382-6. PMID 10542439.

chidb.com

“The Current State of Proteomic Technology”. 2011年10月8日時点のオリジナルよりアーカイブ。2009年7月28日閲覧。

doi.org

Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ (November 1999). “Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery”. Trends in Pharmacological Sciences 20 (11): 432–8. doi:10.1016/S0165-6147(99)01382-6. PMID 10542439.
Tansey EM, Catterall PP (July 1994). “Monoclonal antibodies: a witness seminar in contemporary medical history”. Medical History 38 (3): 322–7. doi:10.1017/s0025727300036632. PMC 1036884. PMID 7934322.
Schwaber J, Cohen EP (August 1973). “Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types”. Nature 244 (5416): 444–7. doi:10.1038/244444a0. PMID 4200460.
Cambrosio A, Keating P (1992). “Between fact and technique: the beginnings of hybridoma technology”. Journal of the History of Biology 25 (2): 175–230. doi:10.1007/BF00162840. PMID 11623041.
Riechmann L, Clark M, Waldmann H, Winter G (March 1988). “Reshaping human antibodies for therapy”. Nature 332 (6162): 323–7. Bibcode: 1988Natur.332..323R. doi:10.1038/332323a0. PMID 3127726.
Altmann DM (November 2018). “A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens”. Immunology 155 (3): 283–284. doi:10.1111/imm.13008. PMC 6187215. PMID 30320408.
Ho M, Feng M, Fisher RJ, Rader C, Pastan I (May 2011). “A novel high-affinity human monoclonal antibody to mesothelin”. International Journal of Cancer 128 (9): 2020–30. doi:10.1002/ijc.25557. PMC 2978266. PMID 20635390.
Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S (2014). “A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood”. PLOS ONE 9 (2): e86184. Bibcode: 2014PLoSO...986184S. doi:10.1371/journal.pone.0086184. PMC 3913575. PMID 24503933.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (September 2003). “Predominant autoantibody production by early human B cell precursors”. Science 301 (5638): 1374–7. Bibcode: 2003Sci...301.1374W. doi:10.1126/science.1086907. PMID 12920303.
Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC (June 2007). “Mature B cells class switched to IgD are autoreactive in healthy individuals”. The Journal of Clinical Investigation 117 (6): 1558–65. doi:10.1172/JCI27628. PMC 1866247. PMID 17510706.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC (2009-01-01). “Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen”. Nature Protocols 4 (3): 372–84. doi:10.1038/nprot.2009.3. PMC 2750034. PMID 19247287.
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC (January 2009). “Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors”. The Journal of Experimental Medicine 206 (1): 139–51. doi:10.1084/jem.20080611. PMC 2626668. PMID 19103878.
Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR, Connors M (October 2013). “Isolation of human monoclonal antibodies from peripheral blood B cells”. Nature Protocols 8 (10): 1907–15. doi:10.1038/nprot.2013.117. PMC 4844175. PMID 24030440.
Ho M (June 2018). “Inaugural Editorial: Searching for Magic Bullets”. Antibody Therapeutics 1 (1): 1–5. doi:10.1093/abt/tby001. PMC 6086361. PMID 30101214.
Vlasak J, Ionescu R (December 2008). “Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods”. Current Pharmaceutical Biotechnology 9 (6): 468–81. doi:10.2174/138920108786786402. PMID 19075686.
Beck A, Wurch T, Bailly C, Corvaia N (May 2010). “Strategies and challenges for the next generation of therapeutic antibodies”. Nature Reviews. Immunology 10 (5): 345–52. doi:10.1038/nri2747. PMID 20414207.
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P (2010). “Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats”. mAbs 2 (6): 613–24. doi:10.4161/mabs.2.6.13333. PMC 3011216. PMID 20818176.
Zhang T, Bourret J, Cano T (August 2011). “Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography”. Journal of Chromatography A 1218 (31): 5079–86. doi:10.1016/j.chroma.2011.05.061. PMID 21700290.
Rathore AS, Winkle H (January 2009). “Quality by design for biopharmaceuticals”. Nature Biotechnology 27 (1): 26–34. doi:10.1038/nbt0109-26. PMID 19131992.
van der Schoot JM, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AM, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JA, Engelfriet M, Caval T, Bentlage AE, Fransen MF, Nederend M, Leusen JH, Heck AJ, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA (August 2019). “Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering”. Science Advances 5 (8): eaaw1822. doi:10.1126/sciadv.aaw1822. PMC 6713500. PMID 31489367.
Siegel DL (January 2002). “Recombinant monoclonal antibody technology”. Transfusion Clinique et Biologique 9 (1): 15–22. doi:10.1016/S1246-7820(01)00210-5. PMID 11889896.
Schmitz U, Versmold A, Kaufmann P, Frank HG (2000). “Phage display: a molecular tool for the generation of antibodies--a review”. Placenta 21 Suppl A (Suppl A): S106-12. doi:10.1053/plac.1999.0511. PMID 10831134.
Boulianne GL, Hozumi N, Shulman MJ (1984). “Production of functional chimaeric mouse/human antibody”. Nature 312 (5995): 643–6. doi:10.1038/312643a0. PMID 6095115.
Chadd HE, Chamow SM (April 2001). “Therapeutic antibody expression technology”. Current Opinion in Biotechnology 12 (2): 188–94. doi:10.1016/S0958-1669(00)00198-1. PMID 11287236.
Lonberg N, Huszar D (1995). “Human antibodies from transgenic mice”. International Reviews of Immunology 13 (1): 65–93. doi:10.3109/08830189509061738. PMID 7494109.
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (December 1990). “Phage antibodies: filamentous phage displaying antibody variable domains”. Nature 348 (6301): 552–4. Bibcode: 1990Natur.348..552M. doi:10.1038/348552a0. PMID 2247164.
Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (December 1991). “By-passing immunization. Human antibodies from V-gene libraries displayed on phage”. Journal of Molecular Biology 222 (3): 581–97. doi:10.1016/0022-2836(91)90498-U. PMID 1748994.
Carmen S, Jermutus L (July 2002). “Concepts in antibody phage display”. Briefings in Functional Genomics & Proteomics 1 (2): 189–203. doi:10.1093/bfgp/1.2.189. PMID 15239904.
Osbourn JK (2002). “Proximity-guided (ProxiMol) antibody selection”. Antibody Phage Display. Methods Mol. Biol.. 178. pp. 201–5. doi:10.1385/1-59259-240-6:201. ISBN 978-1-59259-240-1. PMID 11968489
Osbourn JK, Derbyshire EJ, Vaughan TJ, Field AW, Johnson KS (January 1998). “Pathfinder selection: in situ isolation of novel antibodies”. Immunotechnology 3 (4): 293–302. doi:10.1016/S1380-2933(97)10007-0. PMID 9530562.
Breedveld FC (February 2000). “Therapeutic monoclonal antibodies”. Lancet 355 (9205): 735–40. doi:10.1016/S0140-6736(00)01034-5. PMID 10703815.
Australian Prescriber (2006). “Monoclonal antibody therapy for non-malignant disease”. Australian Prescriber 29 (5): 130–133. doi:10.18773/austprescr.2006.079.
Modified from Carter P (November 2001). “Improving the efficacy of antibody-based cancer therapies”. Nature Reviews. Cancer 1 (2): 118–29. doi:10.1038/35101072. PMID 11905803.

fda.gov

"Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 21 November 2020. 2020年11月21日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
"FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 10 February 2021. 2021年2月9日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。

harvard.edu

ui.adsabs.harvard.edu

Riechmann L, Clark M, Waldmann H, Winter G (March 1988). “Reshaping human antibodies for therapy”. Nature 332 (6162): 323–7. Bibcode: 1988Natur.332..323R. doi:10.1038/332323a0. PMID 3127726.
Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S (2014). “A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood”. PLOS ONE 9 (2): e86184. Bibcode: 2014PLoSO...986184S. doi:10.1371/journal.pone.0086184. PMC 3913575. PMID 24503933.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (September 2003). “Predominant autoantibody production by early human B cell precursors”. Science 301 (5638): 1374–7. Bibcode: 2003Sci...301.1374W. doi:10.1126/science.1086907. PMID 12920303.
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (December 1990). “Phage antibodies: filamentous phage displaying antibody variable domains”. Nature 348 (6301): 552–4. Bibcode: 1990Natur.348..552M. doi:10.1038/348552a0. PMID 2247164.

kymab.com

“Proprietary antibody platform”. 2013年2月3日時点のオリジナルよりアーカイブ。2013年1月17日閲覧。

landesbioscience.com

Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P (2010). “Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats”. mAbs 2 (6): 613–24. doi:10.4161/mabs.2.6.13333. PMC 3011216. PMID 20818176.

ligand.com

investor.ligand.com

“Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock :: Ligand Pharmaceuticals Incorporated (LGND)”. investor.ligand.com. 2021年5月28日閲覧。

mayoclinic.org

“Monoclonal antibody drugs for cancer: How they work”. Mayo Clinic 2018年4月19日閲覧。

medicinenet.com

“Monoclonal Antibodies: List, Types, Side Effects & FDA Uses (Cancer)”. MedicineNet 2018年4月19日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ (November 1999). “Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery”. Trends in Pharmacological Sciences 20 (11): 432–8. doi:10.1016/S0165-6147(99)01382-6. PMID 10542439.
Tansey EM, Catterall PP (July 1994). “Monoclonal antibodies: a witness seminar in contemporary medical history”. Medical History 38 (3): 322–7. doi:10.1017/s0025727300036632. PMC 1036884. PMID 7934322.
Schwaber J, Cohen EP (August 1973). “Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types”. Nature 244 (5416): 444–7. doi:10.1038/244444a0. PMID 4200460.
Cambrosio A, Keating P (1992). “Between fact and technique: the beginnings of hybridoma technology”. Journal of the History of Biology 25 (2): 175–230. doi:10.1007/BF00162840. PMID 11623041.
Riechmann L, Clark M, Waldmann H, Winter G (March 1988). “Reshaping human antibodies for therapy”. Nature 332 (6162): 323–7. Bibcode: 1988Natur.332..323R. doi:10.1038/332323a0. PMID 3127726.
Altmann DM (November 2018). “A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens”. Immunology 155 (3): 283–284. doi:10.1111/imm.13008. PMC 6187215. PMID 30320408.
Ho M, Feng M, Fisher RJ, Rader C, Pastan I (May 2011). “A novel high-affinity human monoclonal antibody to mesothelin”. International Journal of Cancer 128 (9): 2020–30. doi:10.1002/ijc.25557. PMC 2978266. PMID 20635390.
Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S (2014). “A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood”. PLOS ONE 9 (2): e86184. Bibcode: 2014PLoSO...986184S. doi:10.1371/journal.pone.0086184. PMC 3913575. PMID 24503933.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (September 2003). “Predominant autoantibody production by early human B cell precursors”. Science 301 (5638): 1374–7. Bibcode: 2003Sci...301.1374W. doi:10.1126/science.1086907. PMID 12920303.
Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC (June 2007). “Mature B cells class switched to IgD are autoreactive in healthy individuals”. The Journal of Clinical Investigation 117 (6): 1558–65. doi:10.1172/JCI27628. PMC 1866247. PMID 17510706.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC (2009-01-01). “Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen”. Nature Protocols 4 (3): 372–84. doi:10.1038/nprot.2009.3. PMC 2750034. PMID 19247287.
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC (January 2009). “Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors”. The Journal of Experimental Medicine 206 (1): 139–51. doi:10.1084/jem.20080611. PMC 2626668. PMID 19103878.
Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR, Connors M (October 2013). “Isolation of human monoclonal antibodies from peripheral blood B cells”. Nature Protocols 8 (10): 1907–15. doi:10.1038/nprot.2013.117. PMC 4844175. PMID 24030440.
Ho M (June 2018). “Inaugural Editorial: Searching for Magic Bullets”. Antibody Therapeutics 1 (1): 1–5. doi:10.1093/abt/tby001. PMC 6086361. PMID 30101214.
Vlasak J, Ionescu R (December 2008). “Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods”. Current Pharmaceutical Biotechnology 9 (6): 468–81. doi:10.2174/138920108786786402. PMID 19075686.
Beck A, Wurch T, Bailly C, Corvaia N (May 2010). “Strategies and challenges for the next generation of therapeutic antibodies”. Nature Reviews. Immunology 10 (5): 345–52. doi:10.1038/nri2747. PMID 20414207.
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P (2010). “Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats”. mAbs 2 (6): 613–24. doi:10.4161/mabs.2.6.13333. PMC 3011216. PMID 20818176.
Zhang T, Bourret J, Cano T (August 2011). “Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography”. Journal of Chromatography A 1218 (31): 5079–86. doi:10.1016/j.chroma.2011.05.061. PMID 21700290.
Rathore AS, Winkle H (January 2009). “Quality by design for biopharmaceuticals”. Nature Biotechnology 27 (1): 26–34. doi:10.1038/nbt0109-26. PMID 19131992.
van der Schoot JM, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AM, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JA, Engelfriet M, Caval T, Bentlage AE, Fransen MF, Nederend M, Leusen JH, Heck AJ, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA (August 2019). “Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering”. Science Advances 5 (8): eaaw1822. doi:10.1126/sciadv.aaw1822. PMC 6713500. PMID 31489367.
Siegel DL (January 2002). “Recombinant monoclonal antibody technology”. Transfusion Clinique et Biologique 9 (1): 15–22. doi:10.1016/S1246-7820(01)00210-5. PMID 11889896.
Schmitz U, Versmold A, Kaufmann P, Frank HG (2000). “Phage display: a molecular tool for the generation of antibodies--a review”. Placenta 21 Suppl A (Suppl A): S106-12. doi:10.1053/plac.1999.0511. PMID 10831134.
Boulianne GL, Hozumi N, Shulman MJ (1984). “Production of functional chimaeric mouse/human antibody”. Nature 312 (5995): 643–6. doi:10.1038/312643a0. PMID 6095115.
Chadd HE, Chamow SM (April 2001). “Therapeutic antibody expression technology”. Current Opinion in Biotechnology 12 (2): 188–94. doi:10.1016/S0958-1669(00)00198-1. PMID 11287236.
Lonberg N, Huszar D (1995). “Human antibodies from transgenic mice”. International Reviews of Immunology 13 (1): 65–93. doi:10.3109/08830189509061738. PMID 7494109.
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (December 1990). “Phage antibodies: filamentous phage displaying antibody variable domains”. Nature 348 (6301): 552–4. Bibcode: 1990Natur.348..552M. doi:10.1038/348552a0. PMID 2247164.
Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (December 1991). “By-passing immunization. Human antibodies from V-gene libraries displayed on phage”. Journal of Molecular Biology 222 (3): 581–97. doi:10.1016/0022-2836(91)90498-U. PMID 1748994.
Carmen S, Jermutus L (July 2002). “Concepts in antibody phage display”. Briefings in Functional Genomics & Proteomics 1 (2): 189–203. doi:10.1093/bfgp/1.2.189. PMID 15239904.
Osbourn JK (2002). “Proximity-guided (ProxiMol) antibody selection”. Antibody Phage Display. Methods Mol. Biol.. 178. pp. 201–5. doi:10.1385/1-59259-240-6:201. ISBN 978-1-59259-240-1. PMID 11968489
Osbourn JK, Derbyshire EJ, Vaughan TJ, Field AW, Johnson KS (January 1998). “Pathfinder selection: in situ isolation of novel antibodies”. Immunotechnology 3 (4): 293–302. doi:10.1016/S1380-2933(97)10007-0. PMID 9530562.
Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, Shrank WH (February 2018). “Pricing of monoclonal antibody therapies: higher if used for cancer?”. The American Journal of Managed Care 24 (2): 109–112. PMID 29461857.
Breedveld FC (February 2000). “Therapeutic monoclonal antibodies”. Lancet 355 (9205): 735–40. doi:10.1016/S0140-6736(00)01034-5. PMID 10703815.
Modified from Carter P (November 2001). “Improving the efficacy of antibody-based cancer therapies”. Nature Reviews. Cancer 1 (2): 118–29. doi:10.1038/35101072. PMID 11905803.

ncbi.nlm.nih.gov

Tansey EM, Catterall PP (July 1994). “Monoclonal antibodies: a witness seminar in contemporary medical history”. Medical History 38 (3): 322–7. doi:10.1017/s0025727300036632. PMC 1036884. PMID 7934322.
Altmann DM (November 2018). “A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens”. Immunology 155 (3): 283–284. doi:10.1111/imm.13008. PMC 6187215. PMID 30320408.
National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. Recommendation 1: Executive Summary: Monoclonal Antibody Production. Washington (DC): National Academies Press (US); 1999. ISBN 978-0-309-07511-4
Ho M, Feng M, Fisher RJ, Rader C, Pastan I (May 2011). “A novel high-affinity human monoclonal antibody to mesothelin”. International Journal of Cancer 128 (9): 2020–30. doi:10.1002/ijc.25557. PMC 2978266. PMID 20635390.
Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S (2014). “A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood”. PLOS ONE 9 (2): e86184. Bibcode: 2014PLoSO...986184S. doi:10.1371/journal.pone.0086184. PMC 3913575. PMID 24503933.
Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC (June 2007). “Mature B cells class switched to IgD are autoreactive in healthy individuals”. The Journal of Clinical Investigation 117 (6): 1558–65. doi:10.1172/JCI27628. PMC 1866247. PMID 17510706.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC (2009-01-01). “Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen”. Nature Protocols 4 (3): 372–84. doi:10.1038/nprot.2009.3. PMC 2750034. PMID 19247287.
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC (January 2009). “Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors”. The Journal of Experimental Medicine 206 (1): 139–51. doi:10.1084/jem.20080611. PMC 2626668. PMID 19103878.
Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR, Connors M (October 2013). “Isolation of human monoclonal antibodies from peripheral blood B cells”. Nature Protocols 8 (10): 1907–15. doi:10.1038/nprot.2013.117. PMC 4844175. PMID 24030440.
Ho M (June 2018). “Inaugural Editorial: Searching for Magic Bullets”. Antibody Therapeutics 1 (1): 1–5. doi:10.1093/abt/tby001. PMC 6086361. PMID 30101214.
van der Schoot JM, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AM, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JA, Engelfriet M, Caval T, Bentlage AE, Fransen MF, Nederend M, Leusen JH, Heck AJ, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA (August 2019). “Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering”. Science Advances 5 (8): eaaw1822. doi:10.1126/sciadv.aaw1822. PMC 6713500. PMID 31489367.

pmc.ncbi.nlm.nih.gov

Tansey EM, Catterall PP (July 1994). “Monoclonal antibodies: a witness seminar in contemporary medical history”. Medical History 38 (3): 322–7. doi:10.1017/s0025727300036632. PMC 1036884. PMID 7934322.
Altmann DM (November 2018). “A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens”. Immunology 155 (3): 283–284. doi:10.1111/imm.13008. PMC 6187215. PMID 30320408.
Ho M, Feng M, Fisher RJ, Rader C, Pastan I (May 2011). “A novel high-affinity human monoclonal antibody to mesothelin”. International Journal of Cancer 128 (9): 2020–30. doi:10.1002/ijc.25557. PMC 2978266. PMID 20635390.
Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S (2014). “A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood”. PLOS ONE 9 (2): e86184. Bibcode: 2014PLoSO...986184S. doi:10.1371/journal.pone.0086184. PMC 3913575. PMID 24503933.
Koelsch K, Zheng NY, Zhang Q, Duty A, Helms C, Mathias MD, Jared M, Smith K, Capra JD, Wilson PC (June 2007). “Mature B cells class switched to IgD are autoreactive in healthy individuals”. The Journal of Clinical Investigation 117 (6): 1558–65. doi:10.1172/JCI27628. PMC 1866247. PMID 17510706.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC (2009-01-01). “Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen”. Nature Protocols 4 (3): 372–84. doi:10.1038/nprot.2009.3. PMC 2750034. PMID 19247287.
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC (January 2009). “Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors”. The Journal of Experimental Medicine 206 (1): 139–51. doi:10.1084/jem.20080611. PMC 2626668. PMID 19103878.
Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR, Connors M (October 2013). “Isolation of human monoclonal antibodies from peripheral blood B cells”. Nature Protocols 8 (10): 1907–15. doi:10.1038/nprot.2013.117. PMC 4844175. PMID 24030440.
Ho M (June 2018). “Inaugural Editorial: Searching for Magic Bullets”. Antibody Therapeutics 1 (1): 1–5. doi:10.1093/abt/tby001. PMC 6086361. PMID 30101214.
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P (2010). “Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats”. mAbs 2 (6): 613–24. doi:10.4161/mabs.2.6.13333. PMC 3011216. PMID 20818176.
van der Schoot JM, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AM, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JA, Engelfriet M, Caval T, Bentlage AE, Fransen MF, Nederend M, Leusen JH, Heck AJ, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA (August 2019). “Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering”. Science Advances 5 (8): eaaw1822. doi:10.1126/sciadv.aaw1822. PMC 6713500. PMID 31489367.

omtinc.net

“Naturally optimized human antibodies”. 2013年11月11日時点のオリジナルよりアーカイブ。2021年5月28日閲覧。

regeneron.com

“Archived copy”. June 29, 2009時点のオリジナルよりアーカイブ。July 28, 2009閲覧。

springer.com

adisinsight.springer.com

Staff, Adis Insight. Bavituximab profile Last updated Jan 27 2016

thelancet.com

Breedveld FC (February 2000). “Therapeutic monoclonal antibodies”. Lancet 355 (9205): 735–40. doi:10.1016/S0140-6736(00)01034-5. PMID 10703815.

trianni.com

“Proprietary antibody platform”. 2021年5月28日閲覧。

ukbusinesspark.co.uk

“Cambridge Antibody Technology”. 2011年9月28日時点のオリジナルよりアーカイブ。2021年5月28日閲覧。

web.archive.org

“Cytochrome P450 Mediated Drug and Carcinogen Metabolism using Monoclonal Antibodies”. home.ccr.cancer.gov. 2019年6月20日時点のオリジナルよりアーカイブ。2021年5月29日閲覧。
“Archived copy”. June 29, 2009時点のオリジナルよりアーカイブ。July 28, 2009閲覧。
“Proprietary antibody platform”. 2013年2月3日時点のオリジナルよりアーカイブ。2013年1月17日閲覧。
“Naturally optimized human antibodies”. 2013年11月11日時点のオリジナルよりアーカイブ。2021年5月28日閲覧。
“Cambridge Antibody Technology”. 2011年9月28日時点のオリジナルよりアーカイブ。2021年5月28日閲覧。
“The Current State of Proteomic Technology”. 2011年10月8日時点のオリジナルよりアーカイブ。2009年7月28日閲覧。

whatisbiotechnology.org

“The Story of César Milstein and Monoclonal Antibodies”. WhatisBiotechnology.org. 23 September 2020閲覧。

wikipedia.org

en.wikipedia.org

Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna G (2008). “Therapeutic Antibodies and Immunologic Conjugates”. Abeloff's Clinical Oncology (4th ed.). Elsevier
"Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 21 November 2020. 2020年11月21日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
"FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 10 February 2021. 2021年2月9日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。